---

Hemolytic uremic syndrome: An updated review

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Elmukhtar Habas*, Amnna Rayani, Ala Habas, Kalifa Farfar, Eshrak Habas, Ahmed Elmarghani, Abdel-Naser Elzouki

Volume : 1, Issue : 1, Year : 2022

Article Page : 6-13

Suggest article by email

Abstract

Hemolytic uremic syndrome (HUS) is a microangiopathic thrombotic disease, which is classified into atypical, typical, and secondary types. Thrombocytopenia, acute kidney failure, and hemolysis are the main features of HUS regardless of its type. Infection with Shiga toxin-producing Escherichia coli causes typical HUS, and gene mutations trigger atypical HUS, while secondary HUS is associated with bone marrow transplantation, autoimmunity, cancer, and other diseases. New insights into the pathogenesis of HUS have emerged over the past decades, suggesting an important role of the complement system in disease pathogenesis, which has been reinforced by the efficacy of plasma exchange and monoclonal antibodies in its treatment. In this review, we performed an updated review of HUS with a focus on understanding its pathogenesis.

Keywords: Atypical hemolytic uremic syndrome, Hemolysis, Hemolytic uremic syndrome, Renal impairment, Shiga toxin, Thrombocytopenia, Typical hemolytic uremic syndrome

How to cite : Habas E, Rayani A, Habas A, Farfar K, Habas E, Elmarghani A, Elzouki A, Hemolytic uremic syndrome: An updated review. Yemen J Med 2022;1(1):6-13

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International, which allows others to remix, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.